Nicox S.A. (OTCMKTS:NICXF – Free Report) – Equities researchers at HC Wainwright lowered their Q4 2024 EPS estimates for Nicox in a research note issued to investors on Tuesday, April 23rd. HC Wainwright analyst R. Selvaraju now expects that the company will earn ($0.06) per share for the quarter, down from their previous estimate of ($0.05). The consensus estimate for Nicox’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Nicox’s Q1 2024 earnings at ($0.03) EPS, Q2 2024 earnings at ($0.09) EPS, Q3 2024 earnings at ($0.07) EPS and FY2024 earnings at ($0.26) EPS.
Nicox Price Performance
Shares of NICXF stock opened at $0.44 on Thursday. Nicox has a 52-week low of $0.44 and a 52-week high of $0.44. The business has a 50-day simple moving average of $0.44 and a 200-day simple moving average of $0.52.
Nicox Company Profile
Nicox SA operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
See Also
- Five stocks we like better than Nicox
- ETF Screener: Uses and Step-by-Step Guide
- 3 Stocks Leading the U.S. Agriculture Comeback
- What Makes a Stock a Good Dividend Stock?
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What is an Earnings Surprise?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.
